GLPwatch
Exenatide vs Orforglipron
Molecule comparison
Last updated 2026-05-28 15:46 UTCExenatide is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, available as injections under the brand names Byetta and Bydureon. Orforglipron is a newer, non-injectable oral GLP-1 receptor agonist still in development, with no FDA approvals yet for any use.
AI summary of the sources below.
| Exenatide | Orforglipron | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Oral non-peptide GLP-1 receptor agonist |
| Status | Approved | Pipeline |
| Branded products | byetta, bydureon | — |
Compare full details on the Exenatide and Orforglipron pages.